TN2011000299A1 - Anti-igf antibodies - Google Patents

Anti-igf antibodies

Info

Publication number: TN2011000299A1
Authority: TN; Tunisia
Prior art keywords: igf; antibodies; insulin; bind; receptor
Prior art date: 2008-12-12

Application number

TN2011000299A

Other languages

English (en)

Inventor

Eric Borges

Paul Adam

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-12

Filing date

2011-06-10

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-10 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2012-12-17 Publication of TN2011000299A1 publication Critical patent/TN2011000299A1/fr

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
102000038455 IGF Type 1 Receptor Human genes 0.000 abstract 2
108010031794 IGF Type 1 Receptor Proteins 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 1
102000003746 Insulin Receptor Human genes 0.000 abstract 1
108010001127 Insulin Receptor Proteins 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000044162 human IGF1 Human genes 0.000 abstract 1
230000003463 hyperproliferative effect Effects 0.000 abstract 1
230000002297 mitogenic effect Effects 0.000 abstract 1
230000011664 signaling Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Inorganic Chemistry (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

TN2011000299A 2008-12-12 2011-06-10 Anti-igf antibodies TN2011000299A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08171554		2008-12-12
PCT/EP2009/066894 WO2010066868A2 (fr)	2008-12-12	2009-12-11	Anticorps anti-igf

Publications (1)

Publication Number	Publication Date
TN2011000299A1 true TN2011000299A1 (en)	2012-12-17

Family

ID=40512371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000299A TN2011000299A1 (en)	2008-12-12	2011-06-10	Anti-igf antibodies

Country Status (38)

Country	Link
US (4)	US8318159B2 (fr)
EP (2)	EP3064219A3 (fr)
JP (2)	JP5694184B2 (fr)
KR (1)	KR101827332B1 (fr)
CN (3)	CN103396488A (fr)
AP (1)	AP3371A (fr)
AR (1)	AR074726A1 (fr)
AU (1)	AU2009324296B2 (fr)
BR (1)	BRPI0923359B8 (fr)
CA (1)	CA2740341C (fr)
CL (1)	CL2011001431A1 (fr)
CO (1)	CO6390042A2 (fr)
CY (1)	CY1117241T1 (fr)
DK (1)	DK2376116T3 (fr)
EA (1)	EA029178B1 (fr)
EC (1)	ECSP11011126A (fr)
ES (1)	ES2561045T3 (fr)
GE (1)	GEP20146119B (fr)
HR (1)	HRP20160190T1 (fr)
HU (1)	HUE026374T2 (fr)
IL (1)	IL212047A (fr)
MA (1)	MA32888B1 (fr)
ME (1)	ME02377B (fr)
MX (1)	MX2011006055A (fr)
MY (1)	MY150984A (fr)
NZ (3)	NZ597694A (fr)
PE (1)	PE20120415A1 (fr)
PL (1)	PL2376116T3 (fr)
PT (1)	PT2376116E (fr)
RS (1)	RS54423B1 (fr)
SG (2)	SG172107A1 (fr)
SI (1)	SI2376116T1 (fr)
TN (1)	TN2011000299A1 (fr)
TW (1)	TWI471139B (fr)
UA (1)	UA105198C2 (fr)
UY (1)	UY32317A (fr)
WO (1)	WO2010066868A2 (fr)
ZA (1)	ZA201102308B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101477824B1 (ko)	2006-09-29	2015-01-02	온코메드 파마슈티칼스, 인크.	암의 진단 및 치료를 위한 조성물 및 방법
PE20090368A1 (es) *	2007-06-19	2009-04-28	Boehringer Ingelheim Int	Anticuerpos anti-igf
HUE042982T2 (hu)	2007-09-04	2019-07-29	Compugen Ltd	Polipeptidek és polinukleotidok, és alkalmazásuk drogcélpontként drogok és biológiai szerek elõállítására
CA2743072A1 (fr)	2008-11-10	2010-05-14	Novartis Ag	Anticorps anti-peptides igf-1/e humain modifie
RS54423B1 (sr)	2008-12-12	2016-04-28	Boehringer Ingelheim International Gmbh	Anti-igf antitela
US8883145B2 (en)	2009-10-16	2014-11-11	Oncomed Pharmaceuticals, Inc.	Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US20120220594A1 (en) *	2009-10-30	2012-08-30	Bristol-Meyers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
US8551479B2 (en)	2010-09-10	2013-10-08	Oncomed Pharmaceuticals, Inc.	Methods for treating melanoma
US20130330353A1 (en) *	2010-11-16	2013-12-12	Medimmune, Llc	Regimens for treatments using anti-igf antibodies
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
AU2012277376B2 (en)	2011-06-30	2016-11-24	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP6170496B2 (ja)	2011-09-23	2017-07-26	オンコメッドファーマシューティカルズインコーポレイテッド	Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
US20130122005A1 (en) *	2011-10-27	2013-05-16	Paul Adam	Anticancer combination therapy
BR112014018481A2 (pt)	2012-02-01	2017-07-04	Compugen Ltd	anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
WO2014052490A1 (fr)	2012-09-25	2014-04-03	Biogen Idec Ma Inc.	Procédés d'utilisation de polypeptides de facteur ix (fix)
CN102863530A (zh) *	2012-09-26	2013-01-09	李彬	一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用
EP2914961A4 (fr)	2012-10-31	2016-04-20	Oncomed Pharm Inc	Méthodes et surveillance d'un traitement par un antagoniste de dll4
US20140255413A1 (en) *	2013-03-07	2014-09-11	Boehringer Ingelheim International Gmbh	Combination therapy for neoplasia treatment
ES2746136T3 (es)	2013-04-29	2020-03-04	Hoffmann La Roche	Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
RU2687043C2 (ru)	2013-04-29	2019-05-06	Ф. Хоффманн-Ля Рош Аг	МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10508133B2 (en) *	2013-10-18	2019-12-17	Novasep Process	Purification of proteins
US20160324962A1 (en) *	2013-12-19	2016-11-10	Medimmune, Llc	Compositions and methods for treating sarcoma
MX380658B (es)	2014-01-15	2025-03-11	Hoffmann La Roche	Variantes de region fc con union mejorada de la proteina a.
WO2015110560A1 (fr) *	2014-01-24	2015-07-30	Boehringer Ingelheim International Gmbh	Traitement du cancer à l'aide d'un antagoniste des récepteurs du facteur de croissance semblable à l'insuline (igf) en combinaison avec l'exémestane et l'évérolimus
JO3663B1 (ar) *	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3212233B1 (fr)	2014-10-31	2020-06-24	Oncomed Pharmaceuticals, Inc.	Thérapie combinée pour le traitement d'une maladie
US20180104332A1 (en) *	2015-01-16	2018-04-19	The University Of Liverpool	Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy
EP3341021A4 (fr)	2015-08-27	2019-03-13	Celldex Therapeutics, Inc.	Anticorps anti-alk et leurs procédés d'utilisation
JP6967003B2 (ja)	2015-09-23	2021-11-17	メレオバイオファーマ５インコーポレイテッド	がんの処置のための方法および組成物
WO2017055291A1 (fr)	2015-09-28	2017-04-06	Boehringer Ingelheim International Gmbh	Polythérapie anticancéreuse
CN105622730B (zh) *	2016-02-18	2020-06-26	深圳华尔康生物科技有限公司	一种特异性结合igf-1的多肽及其应用
WO2018115380A1 (fr)	2016-12-22	2018-06-28	Boehringer Ingelheim International Gmbh	Nouvelles quinazolines à substitution benzylamino et leurs dérivés en tant qu'inhibiteurs de sos1
KR102014066B1 (ko)	2017-01-06	2019-10-21	에이비엘바이오 주식회사	항 α-syn 항체 및 그 용도
JP2020535180A (ja) *	2017-09-29	2020-12-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療
CN116731173A (zh)	2017-12-14	2023-09-12	Abl生物公司	抗a-syn/igf1r的双特异性抗体及其用途
TWI870922B (zh)	2017-12-21	2025-01-21	德商百靈佳殷格翰國際股份有限公司	作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
KR102404684B1 (ko) *	2019-01-15	2022-06-07	서울대학교산학협력단	인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
EP4157837B1 (fr)	2020-06-02	2024-12-18	Boehringer Ingelheim International GmbH	Thiophènes 2-amino-3-cyano annulés et dérivés pour le traitement du cancer
EP4267250A1 (fr)	2020-12-22	2023-11-01	Qilu Regor Therapeutics Inc.	Inhibiteurs de sos1 et utilisations associées
CN115232114B (zh)	2021-04-23	2023-12-19	上海领泰生物医药科技有限公司	Sos1降解剂及其制备方法和应用
TW202340209A (zh)	2021-12-01	2023-10-16	德商百靈佳殷格翰國際股份有限公司	用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20250129095A1 (en)	2021-12-01	2025-04-24	Boehringer Ingelheim Int'l GmbH Corp.	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN119013272A (zh)	2021-12-01	2024-11-22	勃林格殷格翰国际有限公司	用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
MX2024006681A (es)	2021-12-01	2024-08-26	Boehringer Ingelheim Int	Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer.
US20250145608A1 (en)	2021-12-01	2025-05-08	Boehringer Ingelheim Int'l GmbH Corp.	Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
US20250129096A1 (en)	2021-12-01	2025-04-24	Boehringer Ingelheim Int'l GmbH Corp.	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114671949B (zh) *	2022-04-20	2023-04-28	山西农业大学	一种igf1纳米抗体及其应用
CN119604532A (zh) *	2022-05-20	2025-03-11	瑞泽乐特公司	用于抗胰岛素受体抗体的制剂及其用途
KR20240053520A (ko) *	2022-10-14	2024-04-24	포항공과대학교 산학협력단	Igf-1 수용체 결합 압타머 및 이의 용도
CN117917410A (zh)	2022-10-21	2024-04-23	上海领泰生物医药科技有限公司	pan-KRAS降解剂及其制备方法和应用
JP2025536369A (ja)	2022-10-21	2025-11-05	リーディングタックファーマシューティカル（シャオシン）カンパニー，リミテッド	Ｋｒａｓｇ１２ｄ分解剤及びその製造方法並びに応用
TW202504611A (zh)	2023-03-30	2025-02-01	美商銳新醫藥公司	用於誘導ｒａｓｇｔｐ水解之組合物及其用途
WO2024229406A1 (fr)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Polythérapie pour une maladie ou un trouble lié à ras
US20250019385A1 (en)	2023-05-30	2025-01-16	Boehringer Ingelheim International Gmbh	Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en)	2023-06-28	2025-01-08	Sevenless Therapeutics Ltd	New treatments for pain
WO2025034702A1 (fr)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
GB2633813A (en)	2023-09-21	2025-03-26	Sevenless Therapeutics Ltd	New treatments for pain
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025083426A1 (fr)	2023-10-20	2025-04-24	Sevenless Therapeutics Limited	Nouveaux traitements de la douleur
WO2025137507A1 (fr)	2023-12-22	2025-06-26	Regor Pharmaceuticals, Inc.	Inhibiteurs de sos1 et leurs utilisations
WO2025146548A1 (fr)	2024-01-04	2025-07-10	Sevenless Therapeutics Limited	Inhibiteurs de sos1 utiles pour traiter la douleur et le cancer
WO2025171296A1 (fr)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025210041A1 (fr)	2024-04-03	2025-10-09	Boehringer Ingelheim International Gmbh	Dérivés de benzylamido pyridine bicycliques utilisés en tant qu'inhibiteurs de sos1
WO2025240847A1 (fr)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Inhibiteurs de ras

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
ATE220101T1 (de)	1983-04-25	2002-07-15	Chiron Corp	Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren
WO1985000831A1 (fr)	1983-08-10	1985-02-28	Amgen	Expression microbienne d'un facteur de croissance semblable a l'insuline
AU1232188A (en)	1987-05-29	1988-12-01	Mallinckrodt, Inc.	Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
EP0417193B1 (fr)	1988-05-27	1993-08-04	Centocor, Inc.	Preparation lyophilisee pour la stabilisation de produits a base d'anticorps
AU630882B2 (en)	1988-06-30	1992-11-12	City Of Hope	Insulinomimetic and insulin receptor binding site peptides
CA2058041A1 (fr)	1990-06-27	1991-12-28	Katsuichi Sakano	Anticorps monoclonaux anti-igf-ii
AU6852594A (en)	1993-06-03	1995-01-03	Therapeutic Antibodies Inc.	Production of antibody fragments
WO1995025794A1 (fr)	1994-03-23	1995-09-28	Japan Clinical Laboratories	Anticorps monoclonal anti-igf-i
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
JP2001525339A (ja)	1997-11-27	2001-12-11	コモンウェルスサイエンティフィックアンドインダストリアルリサーチオーガニゼーション	Ｉｇｆ受容体に対するアゴニストおよびアンタゴニストの設計方法
CN1308347C (zh)	1999-04-28	2007-04-04	德克萨斯大学董事会	用于通过选择性抑制vegf来治疗癌症的组合物和方法
DE60141855D1 (de)	2001-01-05	2010-05-27	Amgen Fremont Inc	Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
CN101684158A (zh)	2001-01-17	2010-03-31	特鲁比昂药品公司	结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en)	2001-06-28	2008-09-11	Domantis Limited	Dual-specific ligand and its use
EP1456410A2 (fr)	2001-12-11	2004-09-15	AlgoNomics N.V.	Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
EP1798242B1 (fr)	2002-01-18	2013-01-23	Pierre Fabre Medicament	Anticorps anti-IGF-IR et leurs applications
JP2003310275A (ja)	2002-04-30	2003-11-05	Kyowa Hakko Kogyo Co Ltd	ヒトインスリン様成長因子に対する遺伝子組換え抗体
CA2483848C (fr)	2002-04-30	2012-08-21	Kyowa Hakko Kogyo Co., Ltd.	Anticorps pour facteur de croissance humain semblable a l'insuline
WO2003100008A2 (fr)	2002-05-24	2003-12-04	Schering Corporation	Anticorps anti-igfr humain neutralisant
US8034904B2 (en)	2002-06-14	2011-10-11	Immunogen Inc.	Anti-IGF-I receptor antibody
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
EP1517921B1 (fr)	2002-06-28	2006-06-07	Domantis Limited	Ligands a specificite double et avec une demi-vie augmentee
US20030138430A1 (en) *	2002-09-20	2003-07-24	Stimmel Julie Beth	Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
JP2006523090A (ja)	2002-12-27	2006-10-12	ドマンティスリミテッド	リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
JP2006517581A (ja)	2003-02-13	2006-07-27	ファイザー・プロダクツ・インク	抗インスリン様増殖因子ｉ受容体抗体の使用
CA2518980A1 (fr)	2003-03-14	2004-09-30	Pharmacia Corporation	Anticorps specifiques du recepteur d'igf-i pour le traitement de cancers
CA2524305C (fr)	2003-05-01	2015-12-08	Imclone Systems Incorporated	Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
US7579157B2 (en)	2003-07-10	2009-08-25	Hoffmann-La Roche Inc.	Antibody selection method against IGF-IR
CA2536288A1 (fr)	2003-08-21	2005-03-03	Kyowa Hakko Kogyo Co., Ltd.	Inhibiteur de metastase cancereuse
DE602004030700D1 (de)	2003-09-24	2011-02-03	Kyowa Hakko Kirin Co Ltd	Rekombinanter antikörper gegen humanen insulin-like growth factor
JPWO2005027970A1 (ja)	2003-09-24	2007-11-15	協和醗酵工業株式会社	癌治療用医薬
WO2005058967A2 (fr)	2003-12-16	2005-06-30	Pierre Fabre Medicament	Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
NZ552091A (en)	2004-07-16	2009-09-25	Pfizer Prod Inc	Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
AR053489A1 (es)	2005-05-24	2007-05-09	Morphosys Ag	Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
FR2888850B1 (fr)	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
ME02886B (fr) *	2005-10-12	2018-04-20	Morphosys Ag	Production et profilage d'anticorps thérapeutiques dérivés de la technologie HuCAL GOLD entièrement humains spécifiques à la protéine humaine CD38
ES2385054T3 (es)	2005-12-13	2012-07-17	Medimmune Limited	Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
KR101353706B1 (ko)	2006-02-03	2014-02-18	유니버시티 오브 워싱톤	전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
EA200802061A1 (ru)	2006-03-28	2009-04-28	Байоджен Айдек Эмэй Инк.	Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
CN101578297A (zh) *	2006-04-07	2009-11-11	美国政府健康及人类服务部	治疗肿瘤疾病的抗体组合物和方法
US20080014203A1 (en)	2006-04-11	2008-01-17	Silke Hansen	Antibodies against insulin-like growth factor I receptor and uses thereof
PT2027470E (pt)	2006-06-02	2013-01-28	Pfizer Prod Inc	Ensaio de células tumorais circulantes
ATE537450T1 (de)	2006-06-30	2011-12-15	Schering Corp	Igfbp2-biomarker
WO2008079324A1 (fr)	2006-12-21	2008-07-03	Boston Biomedical Research Institute	Modulation immunologique du facteur de croissance 1 de type insuline destinée à la prévention/traitement du cancer et à prolonger la durée de vie
AR064464A1 (es)	2006-12-22	2009-04-01	Genentech Inc	Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en)	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
WO2008108986A2 (fr)	2007-03-02	2008-09-12	Amgen Inc.	Procédés et compositions permettant de traiter des maladies tumorales
WO2008115470A2 (fr)	2007-03-16	2008-09-25	East Carolina University	Expression de gène hox en tant que biomarqueur pour des agents thérapeutiques igf-1r
CN101668540A (zh)	2007-03-22	2010-03-10	英克隆有限责任公司	稳定的抗体制剂
US8492328B2 (en)	2007-05-17	2013-07-23	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2008144720A2 (fr)	2007-05-21	2008-11-27	University Of Washington	Compositions et procédés pour le traitement de troubles respiratoires
WO2008152422A2 (fr)	2007-06-12	2008-12-18	Astrazeneca Ab	Protéines de liaison spécifiques pour des facteurs de croissance de type insuline et leurs utilisations
PE20090368A1 (es) *	2007-06-19	2009-04-28	Boehringer Ingelheim Int	Anticuerpos anti-igf
WO2009005673A1 (fr)	2007-06-28	2009-01-08	Schering Corporation	Anti-igf1r
US20110052667A1 (en)	2007-06-28	2011-03-03	Sylgen Laboratories, Inc.	Compositions and methods for inhibiting angiogenesis and tumorigenesis
CA2694990A1 (fr)	2007-07-31	2009-02-05	Merck Sharp & Dohme Corp.	Anticorps specifiques de igf-1r utiles dans la detection et le diagnostic de troubles de proliferation cellulaire
EP2190879A1 (fr)	2007-08-01	2010-06-02	Glaxo Group Limited	Nouveaux anticorps
US8426557B2 (en)	2007-08-03	2013-04-23	Affibody Ab	IGF-1R binding polypeptides and their use
US8420315B2 (en)	2007-08-06	2013-04-16	Orion Genomics Llc	Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
EP2197490A2 (fr)	2007-08-28	2010-06-23	Biogen Idec MA, Inc.	Compositions qui se lient à de multiples épitopes de igf-1r
CA2697612A1 (fr)	2007-08-28	2009-03-12	Biogen Idec Ma Inc.	Anticorps anti-igf-1r et leurs utilisations
WO2009039457A1 (fr)	2007-09-19	2009-03-26	The Trustees Of Boston University	Identification de nouvelles voies pour le développement de médicaments destinés à traiter une maladie des poumons
EP2201378A2 (fr)	2007-10-03	2010-06-30	OSI Pharmaceuticals, Inc.	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance 1 du type insuline
US8048621B2 (en)	2007-10-03	2011-11-01	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2247757A2 (fr)	2007-12-18	2010-11-10	Schering Corporation	Biomarqueurs de sensibilité à une thérapie anti-igf1r
US20090258365A1 (en)	2008-03-25	2009-10-15	Terstappen Leon W M M	METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
US20090291088A1 (en)	2008-04-11	2009-11-26	Biogen Idec Ma Inc.	Therapeutic combinations of anti-igf-1r antibodies and other compounds
JP2011519868A (ja)	2008-05-05	2011-07-14	シェーリングコーポレイション	癌を処置するための化学療法剤の連続投与
US20110165145A1 (en)	2008-05-09	2011-07-07	Dransfield Daniel T	Igf-ii/igf-iie binding proteins
NZ589436A (en)	2008-06-03	2012-12-21	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
BRPI0919382A2 (pt)	2008-09-26	2016-01-05	Roche Glycart Ag	anticorpos bi-específicos anti-egfr/anti-igf-1r
CN102224239A (zh)	2008-09-26	2011-10-19	先灵公司	高效价抗体生产
AU2009303453B2 (en)	2008-10-14	2015-02-26	Dyax Corp.	Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
US8163509B2 (en)	2008-10-20	2012-04-24	The Regents Of The University Of Colorado, A Body Corporate	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2743072A1 (fr)	2008-11-10	2010-05-14	Novartis Ag	Anticorps anti-peptides igf-1/e humain modifie
AU2009319856A1 (en)	2008-11-28	2010-06-03	Abbvie Inc.	Stable antibody compositions and methods for stabilizing same
RS54423B1 (sr)	2008-12-12	2016-04-28	Boehringer Ingelheim International Gmbh	Anti-igf antitela
WO2010069858A1 (fr)	2008-12-19	2010-06-24	F. Hoffmann-La Roche Ag	Composition pharmaceutique
EP2381774A4 (fr)	2008-12-23	2012-07-18	Salk Inst For Biological Studi	Procédé de traitement de maladie neurodégénérative
MX2011010911A (es)	2009-04-16	2011-11-02	Merck Sharp & Dohme	Terapia de combinacion que usa un agente o agentes anti-receptor del factor de crecimiento epidermico e inhibidores especificos del factor de crecimiento similar a insulina-1r.
WO2011057064A1 (fr)	2009-11-05	2011-05-12	Brian Long	Traitement du cancer de la prostate à base d'un inhibiteur de igf1r
EP2852685A1 (fr)	2012-03-30	2015-04-01	Merck Sharp & Dohme Corp.	Biomarqueur igf1 pour une thérapie d'inhibition d'igf1r
WO2013169611A1 (fr)	2012-05-09	2013-11-14	Merck Sharp & Dohme Corp.	Compositions et méthodes de traitement du cancer du sein
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
US20140255413A1 (en)	2013-03-07	2014-09-11	Boehringer Ingelheim International Gmbh	Combination therapy for neoplasia treatment
WO2015110560A1 (fr)	2014-01-24	2015-07-30	Boehringer Ingelheim International Gmbh	Traitement du cancer à l'aide d'un antagoniste des récepteurs du facteur de croissance semblable à l'insuline (igf) en combinaison avec l'exémestane et l'évérolimus
WO2017055291A1 (fr)	2015-09-28	2017-04-06	Boehringer Ingelheim International Gmbh	Polythérapie anticancéreuse

2009
- 2009-12-11 RS RS20150877A patent/RS54423B1/sr unknown
- 2009-12-11 SG SG2011042876A patent/SG172107A1/en unknown
- 2009-12-11 AR ARP090104838A patent/AR074726A1/es active IP Right Grant
- 2009-12-11 HR HRP20160190T patent/HRP20160190T1/hr unknown
- 2009-12-11 CA CA2740341A patent/CA2740341C/fr active Active
- 2009-12-11 CN CN2013103138432A patent/CN103396488A/zh active Pending
- 2009-12-11 SI SI200931372T patent/SI2376116T1/sl unknown
- 2009-12-11 DK DK09771361.4T patent/DK2376116T3/en active
- 2009-12-11 TW TW98142592A patent/TWI471139B/zh not_active IP Right Cessation
- 2009-12-11 WO PCT/EP2009/066894 patent/WO2010066868A2/fr not_active Ceased
- 2009-12-11 NZ NZ597694A patent/NZ597694A/xx not_active IP Right Cessation
- 2009-12-11 MX MX2011006055A patent/MX2011006055A/es active IP Right Grant
- 2009-12-11 EP EP15197949.9A patent/EP3064219A3/fr not_active Withdrawn
- 2009-12-11 HU HUE09771361A patent/HUE026374T2/en unknown
- 2009-12-11 BR BRPI0923359A patent/BRPI0923359B8/pt not_active IP Right Cessation
- 2009-12-11 PE PE2011001209A patent/PE20120415A1/es active IP Right Grant
- 2009-12-11 NZ NZ592151A patent/NZ592151A/xx not_active IP Right Cessation
- 2009-12-11 MY MYPI20112684 patent/MY150984A/en unknown
- 2009-12-11 PL PL09771361T patent/PL2376116T3/pl unknown
- 2009-12-11 SG SG2014013841A patent/SG2014013841A/en unknown
- 2009-12-11 UY UY0001032317A patent/UY32317A/es not_active Application Discontinuation
- 2009-12-11 ME MEP-2015-211A patent/ME02377B/fr unknown
- 2009-12-11 GE GEAP200912290A patent/GEP20146119B/en unknown
- 2009-12-11 JP JP2011540115A patent/JP5694184B2/ja active Active
- 2009-12-11 AP AP2011005719A patent/AP3371A/xx active
- 2009-12-11 AU AU2009324296A patent/AU2009324296B2/en not_active Ceased
- 2009-12-11 UA UAA201108588A patent/UA105198C2/ru unknown
- 2009-12-11 CN CN200980148017.9A patent/CN102227226B/zh active Active
- 2009-12-11 EA EA201100918A patent/EA029178B1/ru not_active IP Right Cessation
- 2009-12-11 EP EP09771361.4A patent/EP2376116B1/fr active Active
- 2009-12-11 CN CN2013103122152A patent/CN103396487A/zh active Pending
- 2009-12-11 KR KR1020117012844A patent/KR101827332B1/ko not_active Expired - Fee Related
- 2009-12-11 NZ NZ597692A patent/NZ597692A/xx not_active IP Right Cessation
- 2009-12-11 PT PT97713614T patent/PT2376116E/pt unknown
- 2009-12-11 US US12/636,195 patent/US8318159B2/en not_active Expired - Fee Related
- 2009-12-11 ES ES09771361.4T patent/ES2561045T3/es active Active
2011
- 2011-03-29 ZA ZA2011/02308A patent/ZA201102308B/en unknown
- 2011-03-31 IL IL212047A patent/IL212047A/en active IP Right Grant
- 2011-06-09 MA MA33927A patent/MA32888B1/fr unknown
- 2011-06-10 TN TN2011000299A patent/TN2011000299A1/fr unknown
- 2011-06-10 CL CL2011001431A patent/CL2011001431A1/es unknown
- 2011-06-10 CO CO11072583A patent/CO6390042A2/es active IP Right Grant
- 2011-06-13 EC EC2011011126A patent/ECSP11011126A/es unknown
2012
- 2012-10-17 US US13/653,843 patent/US20130230541A1/en not_active Abandoned
2014
- 2014-06-13 US US14/304,338 patent/US10179810B2/en active Active
2015
- 2015-02-04 JP JP2015019825A patent/JP2015131812A/ja active Pending
2016
- 2016-03-01 CY CY20161100179T patent/CY1117241T1/el unknown
2018
- 2018-12-05 US US16/210,334 patent/US11299538B2/en active Active

Also Published As

Publication number	Publication date
CA2740341C (fr)	2019-05-07
CA2740341A1 (fr)	2010-06-17
NZ592151A (en)	2012-10-26
US20190225681A1 (en)	2019-07-25
KR20110094034A (ko)	2011-08-19
JP5694184B2 (ja)	2015-04-01
SG2014013841A (en)	2014-07-30
CL2011001431A1 (es)	2012-02-17
CN103396487A (zh)	2013-11-20
RS54423B1 (sr)	2016-04-28
HRP20160190T1 (hr)	2016-03-25
UA105198C2 (ru)	2014-04-25
UY32317A (es)	2010-07-30
TW201026327A (en)	2010-07-16
GEP20146119B (en)	2014-07-25
EP3064219A3 (fr)	2016-09-28
ECSP11011126A (es)	2011-07-29
CN102227226B (zh)	2015-05-13
PE20120415A1 (es)	2012-05-09
HK1158933A1 (zh)	2012-07-27
JP2012511315A (ja)	2012-05-24
PT2376116E (pt)	2016-02-24
BRPI0923359A2 (pt)	2015-07-21
ME02377B (fr)	2016-06-20
NZ597692A (en)	2013-08-30
AU2009324296B2 (en)	2016-07-28
AR074726A1 (es)	2011-02-09
MX2011006055A (es)	2011-07-04
CY1117241T1 (el)	2017-04-05
NZ597694A (en)	2013-08-30
EA201100918A1 (ru)	2012-01-30
BRPI0923359B8 (pt)	2021-05-25
EP2376116A2 (fr)	2011-10-19
US20150010574A1 (en)	2015-01-08
DK2376116T3 (en)	2016-02-29
KR101827332B1 (ko)	2018-02-09
WO2010066868A2 (fr)	2010-06-17
BRPI0923359B1 (pt)	2020-09-15
AU2009324296A1 (en)	2010-06-17
US20100150940A1 (en)	2010-06-17
AP3371A (en)	2015-07-31
US8318159B2 (en)	2012-11-27
CO6390042A2 (es)	2012-02-29
ZA201102308B (en)	2011-12-28
CN102227226A (zh)	2011-10-26
EP2376116B1 (fr)	2015-12-09
US11299538B2 (en)	2022-04-12
SG172107A1 (en)	2011-07-28
CN103396488A (zh)	2013-11-20
IL212047A0 (en)	2011-06-30
IL212047A (en)	2016-03-31
US10179810B2 (en)	2019-01-15
MA32888B1 (fr)	2011-12-01
SI2376116T1 (sl)	2016-03-31
US20130230541A1 (en)	2013-09-05
JP2015131812A (ja)	2015-07-23
EA029178B1 (ru)	2018-02-28
WO2010066868A3 (fr)	2010-09-10
MY150984A (en)	2014-03-31
ES2561045T3 (es)	2016-02-24
HUE026374T2 (en)	2016-05-30
EP3064219A2 (fr)	2016-09-07
AP2011005719A0 (en)	2011-06-30
TWI471139B (zh)	2015-02-01
PL2376116T3 (pl)	2016-07-29

Publication	Publication Date	Title
TN2011000299A1 (en)	2012-12-17	Anti-igf antibodies
WO2008155387A3 (fr)	2009-04-30	Anticorps anti-igf
NZ599971A (en)	2014-12-24	Monoclonal antibodies to progastrin and their uses
MX2010004327A (es)	2010-05-13	Anticuerpos anti-vegf completamente humanos y metodos de uso.
PH12014502419A1 (en)	2017-06-05	Specific binding proteins and uses thereof
EA201492253A1 (ru)	2015-06-30	Конструкторы, связывающиеся с ron, и способы их использования
AR075896A1 (es)	2011-05-04	Anticuerpos anti-her (factor de crecimiento epidermico)
NZ623264A (en)	2015-09-25	Sparc binding scfvs
WO2010124009A3 (fr)	2011-01-06	Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
NZ604003A (en)	2015-04-24	Monoclonal antibodies against her2
WO2011041319A3 (fr)	2011-06-30	Protéines de liaison spécifiques et leurs utilisations
MX2017009254A (es)	2017-10-12	Anticuerpos y receptores de antigeno quimerico especificos para ror1.
EP2579895A4 (fr)	2013-12-18	Anticorps anti-vegf et utilisations de ceux-ci
PH12012502022B1 (en)	2019-03-08	Anti-erbb3 antibodies
PH12013500038A1 (en)	2013-03-04	Dual variable domain immunoglobins and uses thereof
MX2013011706A (es)	2014-04-25	Proteinas novedosas de enlace a antigeno.
MX2010002406A (es)	2010-04-27	Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
NZ611076A (en)	2015-09-25	Anti-ngf compositions and use thereof
PH12013500353A1 (en)	2013-03-25	Novel antigen binding proteins
NZ630864A (en)	2017-03-31	Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
WO2011137245A3 (fr)	2012-08-02	Conjugués ligand her2/neu (récepteur 2 du facteur de croissance épidermique humain)-peptide lytique et méthodes d'utilisation associées